Our Strategy

Through a combination of internal research and in-licensing, we are developing multiple product candidates that are designed to activate the immune system to fight cancer. Our products are designed to be used alone or in combination with other immuno-oncology agents.

Three of our programs are focused on disabling a major cancer mechanism of immunosuppression, the adenosine axis.